A Hong Kong listed company plans to acquire all shares of Conflux to enter the Blockchain technology field.

On July 1, 【Block Rhythm】, Hong Kong-listed company Vanguard Medical Biotechnology (00399) announced that on June 30, 2025, the company (, as the buyer ), has entered into a memorandum of understanding with the seller ( Northwestern Foundation ) and Conflux regarding the potential acquisition of all shares of the target company, contingent upon the target company completing the acquisition of Conflux assets in accordance with the agreement with the company.

Conflux is a limited liability company registered in Hong Kong, primarily engaged in the development of blockchain technology. The target company will be a limited liability company to be incorporated in the Cayman Islands and wholly owned by the seller. The company is actively exploring new business opportunities to diversify its revenue sources and implement strategic plans to enhance performance, and the company intends to expand its business into blockchain technology, entering the digital innovation industry.

The signing of the memorandum of understanding indicates that the company is committed to entering the digital innovation industry through potential acquisition activities, in order to develop this new business segment. The company believes that this move will not only diversify the group's business but also bring new profit growth momentum to the group.